Analytical Data
-
Gene name
EIF6
- Application
-
Alternative Names
EIF6；EIF3A；ITGB4BP；Eukaryotic translation initiation factor 6
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P56537
-
Expression Region
1-245aa
-
AA Sequence
MAVRASFENN CEIGCFAKLT NTYCLVAIGG SENFYSVFEG ELSDTIPVVH ASIAGCRIIG RMCVGNRHGL LVPNNTTDQE LQHIRNSLPD TVQIRRVEER LSALGNVTTC NDYVALVHPD LDRETEEILA DVLKVEVFRQ TVADQVLVGS YCVFSNQGGL VHPKTSIEDQ DELSSLLQVP LVAGTVNRGS EVIAAGMVVN DWCAFCGLDT TSTELSVVES VFKLNEAQPS TIATSMRDSL IDSLT
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EIF6 (Eukaryotic Translation Initiation Factor 6) is a pivotal protein involved in the regulation of protein synthesis and ribosome biogenesis. It plays a crucial role in the initiation of translation by facilitating the assembly of the ribosomal subunits and ensuring the proper recruitment of the initiator methionyl-tRNA to the ribosome. Recent studies have highlighted its significance not only in normal cellular processes but also in various pathological conditions, including cancer. Aberrant expression of EIF6 has been linked to the enhancement of oncogenic signaling pathways, promoting cell proliferation and survival. This has made EIF6 an attractive target for therapeutic interventions. Research has increasingly focused on recombinantly producing EIF6 to investigate its structural and functional characteristics, as well as its interactions with other cellular factors. Understanding the mechanisms underlying EIF6 function may provide insights into its role in disease progression and open new avenues for the development of targeted treatments. The study of EIF6 as a recombinant protein has also paved the way for the exploration of its potential as a biomarker and its utility in the design of novel therapeutic strategies aimed at modulating translational control in diseases associated with dysregulated protein synthesis. Overall, the research on EIF6 and its recombinant forms is crucial for unraveling the complexities of translational regulation and its implications in health and disease.
